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Abstract
Background: Juvenile dermatomyositis (JDM) is an auto-immune muscle disease which presents with skin
manifestations and muscle weakness. At least 10% of the patients with JDM present with acquired lipodystrophy.
Laminopathies are caused by mutations in the lamin genes and cover a wide spectrum of diseases including
muscular dystrophies and lipodystrophy. The p.T10I LMNA variant is associated with a phenotype of generalized
lipodystrophy that has also been called atypical progeroid syndrome.
Case presentation: A previously healthy female presented with bilateral proximal lower extremity muscle weakness
at age 4. She was diagnosed with JDM based on her clinical presentation, laboratory tests and magnetic resonance
imaging (MRI). She had subcutaneous fat loss which started in her extremities and progressed to her whole body.
At age 7, she had diabetes, hypertriglyceridemia, low leptin levels and low body fat on dual energy X-ray
absorptiometry (DEXA) scan, and was diagnosed with acquired generalized lipodystrophy (AGL). Whole exome
sequencing (WES) revealed a heterozygous c.29C > T; p.T10I missense pathogenic variant in LMNA, which encodes
lamins A and C. Muscle biopsy confirmed JDM rather than muscular dystrophy, showing perifascicular atrophy and
perivascular mononuclear cell infiltration. Immunofluroscence of skin fibroblasts confirmed nuclear atypia and
fragmentation.
Conclusions: This is a unique case with p.T10I LMNA variant displaying concurrent JDM and AGL. This co-
occurrence raises the intriguing possibility that LMNA, and possibly p.T10I, may have a pathogenic role in not only
the occurrence of generalized lipodystrophy, but also juvenile dermatomyositis. Careful phenotypic characterization
of additional patients with laminopathies as well as individuals with JDM is warranted.
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Background
Juvenile dermatomyositis (JDM) is an autoimmune in-
flammatory disease, which typically affects the proximal
skeletal muscles and presents with characteristic cutane-
ous manifestations in the first 18 years of life [1]. Among
other multi-system manifestations, association with ab-
normal fat distribution and metabolic abnormalities has
been recognized to fit the phenotype of lipodystrophy.
The reported prevalence of lipodystrophy in patients
with JDM is 8–40% In a large multi-center study where
353 patients with JDM were evaluated for having lipody-
strophy, 28 JDM patients were found to have lipodystro-
phy, either generalized or partial [1].
Acquired generalized lipodystrophy (AGL) is character-
ized by progressive loss of subcutaneous adipose tissue,
which starts before adolescence. The fat loss affects the
whole body and results in low serum leptin levels [1, 2].
As a consequence, patients experience various metabolic
complications such as hypertriglyceridemia, hyperphagia,
severe insulin resistance leading to diabetes, and non-
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alcoholic steatohepatitis. These metabolic derangements
often result in serious complications such as recurrent
episodes of acute pancreatitis, premature cardiovascular
disease, and hepatic cirrhosis [1, 3].
Mutations in the LMNA gene cause a wide spectrum of
diseases called laminopathies which include muscular dys-
trophies such as limb girdle muscular dystrophy type 1
(LGMD); progeroid syndromes like Hutchinson Gilford
progeria syndrome (HGPS); and familial partial lipo-
dystrophy (FPLD) which is a lipodystrophy syndrome
[4, 5]. LMNA p.T10I results from a missense muta-
tion (c.29C > T) in exon 1 and leads to a mutant
lamin A protein. A total of nine cases presenting with
this mutation, including the case reported herein,
have recently been described in a case series as part
of a global collaboration [6] with 5 cases presenting with a
phenotype suggestive of AGL [4, 5, 7] and initially deemed
to have either atypical progeroid syndrome or AGL.
However, no other case with this mutation was re-
ported to have lipodystrophy and JDM concurrently
and none have undergone a muscle biopsy to the best
of our knowledge.
Here, we present a unique patient harboring the het-
erozygous c.29C > T (p.T10I) mutation in lamin A/C
who presented originally with JDM followed by what
was diagnosed as AGL. This case provides evidence that
the spectrum of muscle abnormalities caused by lamino-
pathies may be wider than previously recognized.
Methods
Our patient’s metabolic characteristics were previously
reported in a paper describing metabolic response of
lipodystrophy patients to metreleptin. Methods for
metabolic characterization were also included in this re-
port [2]. Informed assent and consent were obtained
from the patient and her mother for genetic testing and
fibroblast collection, as well as from the control patient
with Duchenne muscular dystrophy under approval from
the Institutional Review Board of the University of
Michigan Medical School. Histopathological examin-
ation of fresh frozen muscle biopsy specimen (Fig. 1)
was performed using standard Hematoxyin Eosin(HE)
staining and immunostains for CD3/CD20, CD163/CD4,
C5b9, MHC1, Lamin A/C, following standard procedures
with specific antibodies (Additional file 1: Appendix 1).
Whole exome sequencing (WES) (Fig. 2) and confirmation
via Sanger sequencing were performed as previously de-
scribed [8] (Additional file 1: Appendix 2). Skin fibroblast
cultures obtained from the patient and a control Duchenne
muscular dystrophy patient were analyzed via indirect
immunofluorescence with the lamin A antibody [9].
Case presentation
The patient is a 17 year-old African-American female,
who had normal fat development until age 4 when she
started losing weight and muscle strength. At age 6,
she presented with bilateral proximal lower extremity
Fig. 1 a Hematoxylin Eosin (HE) staining shows prominent perifascicular atrophy (asterisk). b HE staining highlights mononuclear infiltration
around a blood vessel and infiltrating the endomysium. c CD163/CD4 immunostaining highlights several CD4 T-cells (red) in the perivascular and
endomysial space with associated macrophages (brown) (d) MHC1 immunostaining shows abnormal sarcolemmal membrane overexpression in
myocytes, note the normal control below should only highlight capillaries (e) C5b9 immunostaining highlights complement deposition in
capillaries associated with affected fibers; note normal control does not show any capillary immunostain (f) Lamin A/C staining shows nuclear
staining comparable to normal control. Scale bars: 50 μm
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Fig. 2 p.T10I LMNA mutation disrupts nuclear structure. a Integrated Genomics Viewer (IGV) screenshot of 130 bp paired-end whole exome sequencing
reads, represented by horizontal gray bars, demonstrated a single nucleotide change (C to T) at genomic position of chromosome 1 g.156,084,738
(GRCh37/hg19) resulting in a missense alteration at codon 29 of LMNA replacing a threonine (T) with an isoleucine (I): NM_170707.3(LMNA):c.29C > T
(p.T10I) (b) Skin fibroblast cell cultures of our patient with heterozygous p.T10I LMNA mutation and a Duchenne muscular dystrophy patient were
analyzed by immunoflourescence using an antibody to lamin A. Cell cultures were stained with primary lamin A antibody, followed by 4′,6-diamidino-2
phenylindole (DAPI) nuclear staining and with the Alexa 488 goat anti-rabbit IgG. Scale bar: 200 μm. c Higher magnification images of the nuclear
staining shown in (b); scale bar: 50 μm. Arrows in panel (b) indicate fragmented nuclei; arrows in panel (c) indicate examples of atypically shaped nuclei
and/or nuclei with ruffles of lamin A staining
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weakness and had elevated levels of erythrocyte sedimenta-
tion rate (ESR), C-reactive protein (CRP), creatinine kinase
(CK), lactate dehydrogenase (LDH), aspartate aminotrans-
ferase (AST) and aldolase. T2-weighted (magnetic reson-
ance imaging).
MRI images of her lower extremities showed hyperin-
tensity in her quadriceps muscles consistent with myo-
sitis. On the basis of her clinical presentation, laboratory
results and MRI, she was diagnosed with JDM. Her pres-
entation was reported previously [2]. On physical exam-
ination, she had generalized loss of subcutaneous fat
including her face, a high-arched palate, micrognathia, a
small mid-face and bilateral parotid enlargement. She
also had progressive contractures in most upper extrem-
ity joints, calcinosis on her knuckles and mottled skin
throughout her upper body. She had hepatosplenomegaly
and non-alcoholic steatohepatitis. Her leptin level was < 0.
7 ng/dL, and her DEXA scan showed 9.3% body fat. She
was diagnosed with AGL, with associated diabetes and
polycystic ovarian syndrome. In the next 7 years, she had
severe elevations in triglycerides > 10,000 mg/dL and mul-
tiple episodes of acute pancreatitis and diabetic ketoacido-
sis. Echocardiogram performed at age 9 showed moderate
aortic stenosis and atrial septal defect, ostium secundum
type. She also had ovarian cysts and nephromegaly due to
bilateral renal cysts. Despite being on methotrexate for
JDM, her serum muscle enzyme levels fluctuated. For her
lipodystrophy, she was treated with metreleptin [2].
Whole exome sequencing done at age 16 identified a
heterozygous missense mutation (c.29C > T) in LMNA
resulting in p.T10I substitution which is considered to
be pathogenic (Fig. 2). This was not maternally inherited.
The patient’s father had sudden cardiac death at age 49,
so a blood sample was not available. He was reported to
be thin, especially on the face and was diabetic in the
last 2 years of his life. Further he had history of thyroid
cancer as conveyed by patient and her mother. The
patient’s WES data was interrogated for pathogenic vari-
ants in the genes that might be related to JDM, such as
TNF, HLADRB1, IL1RN, IL1A, IL1B, ISG15, BLK and
CCL21. No pathogenic variants were found in these
genes. Of note, PLCL1 gene was not covered in the
patient’s WES data, hence was not screened. A muscle
biopsy was obtained from her right quadriceps muscle
which confirmed the earlier diagnosis of JDM, including
perifascicular atrophy, perivascular mononuclear cell infil-
trates and upregulation of sarcolemmal MHC1 (Fig. 1).
Immunofluorescence staining of skin fibroblasts from the
patient and a control patient with Duchenne muscular dys-
trophy which is used as a non- LMNA related control both
displayed positive nuclear staining for lamin A (Fig. 2).
However, LMNA mutant nuclei exhibited greater nuclear
atypia and fragmentation compared to the control fibro-
blasts from an unrelated myopathy without LMNA
mutations. Our results in Fig. 2 are consistent with previ-
ous reports that scored atypical nuclei which reported that
control fibroblasts have occaisonal atypical nuclei in ~ 19%
of cells while the number of atypical nuclei in fibroblasts
from patients with lamin A/C mutations were much more
common (33–92%) [8]. It should be noted that it is very
reasonable to use Duchenne muscular dystrophy (DMD)
as a control, and although there is one report of a
case study of a DMD patient with altered nuclear
structure similar to LMNA related muscular dys-
trophy, further analysis showed this patient also car-
ried a mutation in Nesprin-1, and patients with other
mutations in dystrophin showed no significant differ-
ences in nuclear structure from non-disease human
fibroblasts [10].
Discussion
Here we report a patient with concurrent JDM and AGL
with some atypical features. She was found to have a p.
T10I mutation in the lamin A/C region encoding the N-
terminal head; such mutations were previously associ-
ated with generalized lipodystrophy in patients classified
as having atypical progeroid syndrome [4, 5, 7]. To our
knowledge, she is the first with this mutation to present
with both generalized lipodystrophy and biopsy proven
JDM. In fact, the nine cases observed including our case
were summarized in a new paper recently and none of
the others presented with muscle disease [6]. Because
different lamin A/C mutations cause various muscle
disorders as well as lipodystrophy phenotypes [5], we
propose that the presence of JDM and AGL might be
linked to the p.T10I mutation in this patient.
The wide spectrum of diseases within the laminopa-
thies is attributed to different mutations in LMNA lead-
ing to various modifications in the tertiary structure of
the lamin A/C proteins. In addition to disruptions in the
nuclear structure leading to fragility, some mutations are
known to interfere with cell division, alter interactions
with certain transcription factors, or modify gene ex-
pression (8). It was proposed earlier that the p.T10I
mutation, which is located in the extreme amino
terminus of the lamin A protein, might have a causal
role in detachment of chromatin from the nuclear lam-
ina as well as disruption of lamin polymerization [5, 8].
Four previous reports associate inflammatory myositis
with LMNA variants, suggesting that the muscle disease
of laminopathy is not restricted to muscular dystrophy
and may be more complicated [11–14].
While muscle biopsies are now rarely performed in sus-
pected cases of LMNA mutations causing muscular dys-
trophy, previous reports have shown that some LMNA
muscular dystrophy patients have marked inflammatory
cell infiltrates, although without noted upregulation of
MHC [15]. More careful analysis of potential causes of the
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muscle pathology may reveal greater overlap between the
lipodystrophy syndromes, myositis, and muscle diseases
associated with lamin A/C mutations than previously
suggested. Based on previous work, JDM appears to be a
heterogeneous phenotype and to date, no clear molecular
etiology has emerged although HLA associations and
some genome wide association study (GWAS) loci have
been reported [16]. Our case and a few other published re-
ports [12–14] raise the possibility that nuclear lamins may
be implicated in the development of inflammatory myop-
athies. We propose that deeper muscular phenotyping of
laminopathies in patients who present with this genotype
should be undertaken to understand if we are correct
especially if abnormalities in muscle enzymes can be dem-
onstrated. The selective genetic modifiers that result in
different tissue manifestations despite having the same
mutation remain to be defined.
Conclusion
LMNA mutations are associated with an array of
diseases called laminopathies which include muscular
dystrophy and lipodystrophy, among other diseases.
However, no certain causal relation between LMNA mu-
tations and inflammatory muscle diseases has been
established. We posit that both inflammatory muscle
disease and generalized lipodystrophy in this patient are
due to the lamin A/C T10I variant, although a multifac-
torial etiology cannot be excluded. This case broadens
the spectrum of laminopathies; more importantly, it pro-
vides the first potential molecular link to the known as-
sociation between JDM and lipodystrophy syndromes.
Further studies probing the interaction between nuclear
envelope proteins and the immunotranscriptome are
needed to unlock the mysteries of this long recognized
but unexplained association.
Additional file
Additional file 1: Appendix 1. Antibodies used for
immunohistochemistry. Histopathological examination using fresh frozen
muscle biopsy specimen from the patient was performed using the
immunostains for: MHC1, Lamin A/C, C5b9, CD163/CD4, CD3/CD20. The
antibodies used and respective protocols are shown. Appendix 2 Sanger
sequencing chromatogram completed by a CLIA certified laboratory.
Data from Sanger sequencing was used to confirm the patient’s whole
exome sequencing (WES) results. Similar to the WES data, Sanger
sequencing chromatogram revealed a heterozygous c.29 C > T mutation
in exon 1. In the figure, both the wild type and the patient’s data with
this mutation are shown. (PDF 618 kb)
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